Haemonetics Corporation (NYSE:HAE) finished Friday with an addition of $0.12 to close at $71.75, an upside of 0.17 percent. An average of 361,440 shares of common stock have been traded in the last five days. There was a gain of $1.84 in the past week, and it reached a new high 22 times over the past 12 months. The last 20 days have seen an average of 383,985 shares traded, while the 50-day average volume stands at 450,470.
HAE stock has increased by 3.04% in the last month. The company shares reached their 1-month lowest point of $66.02 on 10/12/21. With the stock rallying to its 52-week high on 02/09/21, shares of the company touched a low of $49.26 and a high of $142.11 in 52 weeks. It has reached a new high 10 times so far this year and lost -39.58% or -$47.00 in price. In spite of this, the price is down -49.51% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
46 days have passed since Haemonetics Corporation (HAE) last reported insider trading activity. Llorens Josep, who is EVP, Global Manufacturing, most recently acquired $100 shares at $64.61 per share on Sep 07. In this transaction, the insider spent $6,461. EVP, Chief Financial Officer, Burke William P. Mr., disposed of 22,667 shares at a price of $60.51 on Aug 23. The insider now owns more than $1,371,580 worth of shares. Prior to that, EVP, Chief Financial Officer Burke William P. Mr. went on to Sale 4,293 shares at $66.60 each on Jul 01. An amount of $285,914 was transacted.
Haemonetics Corporation (HAE) has a trailing price-to-earnings (P/E) ratio of 57.03, which compares with the 26.30 for the broader industry and 33.43 for the sector. In the last five years, Haemonetics Corporation’s PE ratio has ranged between 772.64 and 33.43. The stock’s beta is 0.28. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.10, the price-to-book (PB) ratio at 5.40, and the price-to-cash flow ratio at 71.27.
The quick ratio of Haemonetics Corporation for the three months ended June 29 was 1.60, and the current ratio was 3.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.13 and a total debt to equity ratio of 1.16 for the quarter ending June 29. Haemonetics Corporation’s EBITDA margin for the year ending June 29 is 20.54%, while its operating margin for the same period stands at 8.80%. Its gross profit as reported stood at $397.84 million compared to revenue of $870.46 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Haemonetics Corporation’s return on assets was 4.10%. For the broader industry, ROE averaged 3.96 over the past year.
For the three-month period that ended June 29, Haemonetics Corporation had $767.35 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$4.45 million in the quarter, while revenues were grew 336.63%. The analyst consensus anticipated Haemonetics Corporation’s latest quarter earnings to come in at $0.45 per share, but it turned out to be $0.5, a 11.10% surprise. For the quarter, EBITDA amounted to $32.74 million. Shareholders own equity worth $51.03 million.
From a technical analysis perspective, let’s take a brief look at Haemonetics Corporation (HAE) price momentum. RSI 9-day as of the close on 22 October was 61.13%, suggesting the stock is Neutral, with historical volatility in this time frame at 34.43%.
As of today, HAE’s price is $70.18 +2.63% or $1.84 from its 5-day moving average. HAE is currently trading +3.25% higher than its 20-day SMA and +28.42% higher than its 100-day SMA. However, the stock’s current price level is +14.62% above the SMA50 and -43.76% below the SMA200.
The stochastic %K and %D were 84.16% and 67.62%, respectively, and the average true range (ATR) was 2.09. With the 14-day stochastic at 88.42% and the average true range at 2.07, the RSI (14) stands at 59.40%. The stock has reached 1.54 on the 9-day MACD Oscillator while the 14-day reading was at 2.36.
The consensus rating for Haemonetics Corporation (HAE) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell HAE, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 6 others rate it as a “buy”.
What is HAE’s price target for the next 12 months?
Analysts predict a range of price targets between $68.00 and $90.00, with a median target of $77.50. Taking a look at these predictions, the average price target given by analysts for Haemonetics Corporation (HAE) stock is $79.25.